A Phase 2 interventional study of Bivamelagon and Placebo in Hypothalamic Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 10 sites in 2 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Sexual Infantilism with a site in United States — 3 open to participants now, 6 under way, 2 of them phase 3. Sexual Infantilism · United States.
Among the 14 studies in Sexual Infantilism with a site in United States, this one is the 6th largest by enrollment, is one of 3 that started in 2024, is one of 7 in phase 2, and was the 8th registered.
23 studies on the registry are indexed under Sexual Infantilism; 5 are open to participants now.
Browse Sexual Infantilism studies →3 of the 14 studies in Sexual Infantilism with a site in United States are open now. Recruiting first, the newest first:
Rhythm Pharmaceuticals, Inc. · Sites in United States, United Kingdom
Ages 4+
Grace Kim · Sites in United States
Ages 18–26
Rhythm Pharmaceuticals, Inc. · Sites in United States, United Kingdom
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Sexual Infantilism studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 4 · Phase 4 1
First in 2010; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is close to the median of 30 across 20 interventional studies indexed under Sexual Infantilism.
Median enrollment 27 across the 14 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 14 have an industry lead sponsor. The 7 most frequent:
Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
Rhythm Pharmaceuticals, Inc. has 7 studies filed under Sexual Infantilism — fewer than ten, so there is no comparison to draw.
2 of the studies in Sexual Infantilism with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06760546Phase 3Rhythm Pharmaceuticals, Inc.A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) | 2027-03-13 |
| NCT06239116Rhythm Pharmaceuticals, Inc.A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment | 2027-05-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Sexual Infantilism with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study was to determine how well LB54640 (also known as bivamelagon) worked and how safe it was in participants with Hypothalamic Obesity (HO). The study evaluated the effect of bivamelagon on safety, weight reduction, hunger, and quality of life in participants 12 years of age and older with HO. Participants took an oral daily dose of either bivamelagon (low, middle, or high dose) or placebo through Week 14. Eligible participants who consented to continue in the study after Week 14 took an oral daily dose of bivamelagon through Week 52.
The criteria were revised on the registry on Oct 30, 2026. See what changed
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were randomized to receive bivamelagon low dose (200 mg), middle dose (400 mg), or high dose (600 mg), or placebo by oral administration in a 1:1:1:1 ratio.
Drug: Bivamelagon
Participants were randomized to receive bivamelagon low dose (200 mg), middle dose (400 mg), or high dose (600 mg), or placebo by oral administration in a 1:1:1:1 ratio.
Drug: Bivamelagon
Participants were randomized to receive bivamelagon low dose (200 mg), middle dose (400 mg), or high dose (600 mg), or placebo by oral administration in a 1:1:1:1 ratio.
Drug: Bivamelagon
Participants were randomized to receive bivamelagon low dose (200 mg), middle dose (400 mg), or high dose (600 mg), or placebo by oral administration in a 1:1:1:1 ratio.
Drug: Placebo
Eligible participants who provided consent to continue into the open-label portion of the study received open-label bivamelagon.
Drug: Bivamelagon
Oral daily administration
Also known as: LB54640
Placebo matched to LB54640
Treatment Phase: Mean Percentage Change From Baseline to Week 14 in Body Mass Index (BMI)
BMI was calculated as weight (kilograms \[kg\])/height (squared meters \[m\^2\]). Least square mean (LSM) and standard error (SE) were calculated using analysis of covariance (ANCOVA) model with treatment group, randomization stratification factor (≥18 years old vs \<18 years old) as factors and baseline BMI as a covariate.
Time frame: Baseline, Week 14
Treatment Phase: Mean Percentage Change From Baseline to Weeks 6 and 10 in BMI
BMI was calculated as weight (kg)/height (m\^2). Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
Time frame: Baseline, Week 6 and Week 10
Treatment Phase: Mean Change From Baseline in BMI
BMI was calculated as weight (kg)/height (m\^2).
Time frame: Baseline, Week 6, Week 10, and Week 14
Treatment Phase (Participants < 18 Years): Mean Change From Baseline in the Gender- and Age-specific BMI Z-Score
The BMI Z-scores were measures of relative weight adjusted for child age and sex. Given a child's age, sex, BMI, and an appropriate reference standard, a BMI Z-score can be determined. The BMI Z-scores were calculated using the Lambda Mu and Sigma method following the 2007 World Health Organization (WHO) reference. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease in BMI Z-score (\< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (\> 0) indicated an increase in BMI from Baseline.
Time frame: Baseline, Week 6, Week 10, and Week 14
Treatment Phase (Participants < 18 Years): Mean Change From Baseline in the Percentage of the Gender- and Age-specific 95th Percentile of BMI
The BMI values were expressed as a percentage of the gender- and age-specific 95th percentile following the 2000 Centers for Disease Control (CDC) BMI-for-Age Growth Charts form.
Time frame: Baseline, Week 6, Week 10, and Week 14
Treatment Phase: Mean Change From Baseline in Body Weight
Time frame: Baseline, Week 6, Week 10, and Week 14
Treatment Phase: Mean Percentage Change From Baseline in Body Weight
Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
Time frame: Baseline, Week 6, Week 10, and Week 14
Treatment Phase: Percentage of Participants Who Achieved at Least a ≥5% or ≥10% Reduction in Body Weight
Time frame: Baseline to Week 14
Treatment Phase: Percentage of Participants Who Achieved at Least a ≥5% or ≥10% Reduction in BMI
BMI was calculated as weight (kg)/height (m\^2).
Time frame: Baseline to Week 14
Treatment Phase: Mean Change From Baseline in Waist Circumference
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest.
Time frame: Baseline, Week 6, Week 10, and Week 14
Treatment Phase: Mean Percentage Change From Baseline in Waist Circumference
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
Time frame: Baseline, Week 6, Week 10, and Week 14
Treatment Phase: Mean Change From Baseline in Waist-to-hip Circumference Ratio
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference.
Time frame: Baseline, Week 6, Week 10, and Week 14
Treatment Phase: Mean Percentage Change From Baseline in Waist-to-hip Circumference Ratio
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
Time frame: Baseline, Week 6, Week 10, and Week 14
Treatment Phase: Mean Change From Baseline in Body Composition
Body composition included fat and lean body mass and was assessed by dual energy x-ray absorptiometry (DEXA).
Time frame: Baseline, Week 14
Treatment Phase: Mean Percentage Change From Baseline in Body Composition
Body composition included fat and lean body mass and was assessed by DEXA. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
Time frame: Baseline, Week 14
Treatment Phase: Mean Change From Baseline in the Weekly Average of the Daily Most Hunger Score
Participants who were able to validly and reliably self-report were administered "Hunger Questions for Participants ≥12 Years of Age©." This questionnaire comprised 2 items (average and most hunger) that were designed to be evaluated separately (rather than as a composite score). Each item asked participants to rate their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all and 10 = hungriest possible) with a recall period of 24 hours. Data reported are for mean change from baseline in the weekly average daily most hunger score.
Time frame: Baseline, Week 14
Treatment Phase: Mean Change From Baseline in the Weekly Average of the Symptoms of Hyperphagia Composite Score
Participants who were able to self-report were administered the Symptoms of Hyperphagia: Patient© Version. The questionnaire consisted of 4 items related to the frequency of a participant's hyperphagia symptoms on a scale (never \[score 0\], 1 or 2 times \[score 1\], 3 or more times \[score 2\]) over the previous 24 hours. Caregivers of participants who could not self report were administered the Symptoms of Hyperphagia: Caregiver© Version which consisted of 5 items that included caregivers assessing the frequency of hyperphagia symptoms on a scale (never \[score 0\], 1 or 2 times \[score 1\], 3 or more times \[score 2\]) over the previous 24 hours for the person in their care. The composite score was derived by adding up all item scores and dividing by total number of items answered. The full range of the composite score was 0-2, with higher scores representing more hyperphagia. Data are reported for mean change from baseline in weekly average of symptoms of hyperphagia composite score.
Time frame: Baseline, Week 14
Open-label Extension Phase: Mean Change From Baseline in BMI
BMI was calculated as weight (kg)/height (m\^2).
Time frame: Baseline, Week 28 and Week 52
Open-label Extension Phase: Mean Percentage Change From Baseline in BMI
BMI was calculated as weight (kg)/height (m\^2). Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
Time frame: Baseline, Week 28 and Week 52
Open-label Extension Phase: Mean Change From Baseline in Body Weight
Time frame: Baseline, Week 28 and Week 52
Open-label Extension Phase: Mean Percentage Change From Baseline in Body Weight
Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
Time frame: Baseline, Week 28 and Week 52
Open-label Extension Phase: Mean Change From Baseline in Waist Circumference
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest.
Time frame: Baseline, Week 28 and Week 52
Open-label Extension Phase: Mean Percentage Change From Baseline in Waist Circumference
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
Time frame: Baseline, Week 28 and Week 52
Open-label Extension Phase: Mean Change From Baseline in Waist-to-hip Circumference Ratio
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference.
Time frame: Baseline, Week 28 and Week 52
Open-label Extension Phase: Mean Percentage Change From Baseline in Waist-to-hip Circumference Ratio
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
Time frame: Baseline, Week 28 and Week 52
Open-label Extension Phase: Mean Change From Baseline in Body Composition
Body composition included fat and lean body mass and was assessed by DEXA.
Time frame: Baseline, Week 52
Open-label Extension Phase: Mean Percentage Change From Baseline in Body Composition
Body composition included fat and lean body mass and was assessed by DEXA. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
Time frame: Baseline, Week 52
Treatment Phase: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) or Adverse Event of Special Interest (AESI)
A TEAE was any undesirable and unintended medical event occurring to a participant in a clinical study and which did not necessarily have a causal relationship with the study drug, with onset or worsening after the start of study drug. AESIs were events of scientific and medical interest specific to further the understanding of the safety profile of the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Day 1 to Week 14
Open-label Extension Phase: Number of Participants Who Experienced a TEAE or AESI
A TEAE was any undesirable and unintended medical event occurring to a participant in a clinical study and which does not necessarily have a causal relationship with the study drug, with onset or worsening after the start of study drug. AESIs were events of scientific and medical interest specific to the further understanding of the safety profile of the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Week 14 to Week 56
Treatment Phase: Number of Participants Who Experienced a Mild, Moderate, Severe, Life-threatening or Fatal TEAE
TEAEs were evaluated by the investigator according to the definitions below using the following guidelines: * Mild - Asymptomatic or mild symptoms; clinical or diagnostic observations only; no intervention indicated; no disruption to daily activity. * Moderate - Discomfort sufficient to reduce or affect normal daily activity. * Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; inability to work or perform normal daily activity. * Life-threatening consequences; urgent intervention indicated. * Fatal outcome. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Day 1 to Week 14
Open-label Extension Phase: Number of Participants Who Experienced a Mild, Moderate, Severe, Life-threatening or Fatal TEAE
TEAEs were evaluated by the investigator according to the definitions below using the following guidelines: * Mild - Asymptomatic or mild symptoms; clinical or diagnostic observations only; no intervention indicated; no disruption to daily activity. * Moderate - Discomfort sufficient to reduce or affect normal daily activity. * Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; inability to work or perform normal daily activity. * Life-threatening consequences; urgent intervention indicated. * Fatal outcome. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Week 14 to Week 56
Treatment Phase: Maximum Observed Concentration of Bivamelagon in Plasma (Cmax)
Pharmacokinetic (PK) parameters were derived using noncompartmental methods. Cmax was obtained directly from the observed concentration versus time data. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.
Time frame: Week 0 and Week 10: Pre-dose and 1, 2, 4, 6, and 24 hours post-dose
Treatment Phase: Time to Cmax (Tmax)
PK parameters were derived using noncompartmental methods. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.
Time frame: Week 0 and Week 10: Pre-dose and 1, 2, 4, 6, and 24 hours post-dose
Treatment Phase: Area Under the Concentration-time Curve From 0 to Last Quantifiable Concentration (AUC0-t)
PK parameters were derived using noncompartmental methods.AUC0-t was calculated by the linear up/log down trapezoidal summation. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.
Time frame: Week 0 and Week 10: Pre-dose and 1, 2, 4, 6, and 24 hours post-dose
Treatment Phase: Trough Plasma Concentration (Ctrough)
PK parameters were derived using noncompartmental methods. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.
Time frame: Weeks 1, 2, 6, 10, and 14: Pre-dose
| Milestone | Bivamelagon 200 mg | Bivamelagon 400 mg | Bivamelagon 600 mg | Placebo |
|---|---|---|---|---|
| Started | 6 | 7 | 8 | 7 |
| Received study drug | 6 | 7 | 8 | 7 |
| Completed | 6 | 6 | 8 | 7 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Milestone | Bivamelagon 200 mg | Bivamelagon 400 mg | Bivamelagon 600 mg | Placebo |
|---|---|---|---|---|
| Started | 6 | 6 | 7 | 7 |
| Completed | 5 | 6 | 7 | 6 |
| Not completed | 1 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
| Withdrew: Other than specified | 1 | 0 | 0 | 0 |
BMI was calculated as weight (kilograms \[kg\])/height (squared meters \[m\^2\]). Least square mean (LSM) and standard error (SE) were calculated using analysis of covariance (ANCOVA) model with treatment group, randomization stratification factor (≥18 years old vs \<18 years old) as factors and baseline BMI as a covariate.
| percentage change | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Treatment Phase: Mean Percentage Change From Baseline to Week 14 in Body Mass Index (BMI) | -2.62 ± 1.683 | -8.39 ± 1.738 | -9.98 ± 1.557 | 2.52 ± 1.868 |
BMI was calculated as weight (kg)/height (m\^2). Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
| percentage change | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Week 6 | -1.06 ± 1.499 | -5.65 ± 1.600 | -5.80 ± 3.651 | 0.02 ± 2.087 |
| Week 10 | -6.47 ± 8.377 | -8.27 ± 2.304 | -8.07 ± 4.503 | 0.64 ± 2.247 |
BMI was calculated as weight (kg)/height (m\^2).
| kilograms per square meter (kg/m^2) | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Week 6 | -0.45 ± 0.610 | -2.13 ± 0.839 | -2.47 ± 1.692 | 0.05 ± 0.766 |
| Week 10 | -2.25 ± 2.670 | -3.08 ± 1.045 | -3.36 ± 2.000 | 0.31 ± 0.945 |
| Week 14 | -1.10 ± 1.285 | -3.31 ± 1.508 | -4.12 ± 2.542 | 0.88 ± 1.154 |
The BMI Z-scores were measures of relative weight adjusted for child age and sex. Given a child's age, sex, BMI, and an appropriate reference standard, a BMI Z-score can be determined. The BMI Z-scores were calculated using the Lambda Mu and Sigma method following the 2007 World Health Organization (WHO) reference. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease in BMI Z-score (\< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (\> 0) indicated an increase in BMI from Baseline.
| BMI z-score | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Week 6 | -0.02 ± 0.055 | -0.30 ± 0.030 | -0.15 ± 0.039 | -0.04 ± 0.105 |
| Week 10 | -0.53 ± 0.774 | -0.44 ± 0.100 | -0.23 ± 0.121 | -0.04 ± 0.046 |
| Week 14 | -0.04 ± 0.104 | -0.49 ± 0.235 | -0.33 ± 0.270 | 0.06 ± 0.035 |
The BMI values were expressed as a percentage of the gender- and age-specific 95th percentile following the 2000 Centers for Disease Control (CDC) BMI-for-Age Growth Charts form.
| percentage of the 95th percentile of BMI | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Week 6 | -0.38 ± 1.401 | -7.11 ± 2.249 | -3.96 ± 1.386 | -1.37 ± 2.848 |
| Week 10 | -11.56 ± 16.321 | -10.000 ± 3.918 | -5.79 ± 3.269 | -1.19 ± 1.122 |
| Week 14 | -1.27 ± 2.978 | -10.71 ± 5.741 | -8.43 ± 7.408 | 1.16 ± 0.180 |
| kilograms | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Week 6 | -1.70 ± 1.816 | -5.79 ± 2.556 | -6.58 ± 4.020 | 0.37 ± 1.991 |
| Week 10 | -2.88 ± 2.947 | -8.32 ± 2.959 | -8.77 ± 5.567 | 1.64 ± 2.772 |
| Week 14 | -2.83 ± 4.864 | -8.97 ± 4.255 | -10.49 ± 7.332 | 2.97 ± 3.681 |
Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
| percentage change | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Week 6 | -1.25 ± 1.295 | -5.61 ± 1.665 | -5.98 ± 3.550 | 0.41 ± 1.941 |
| Week 10 | -2.32 ± 2.403 | -8.16 ± 2.104 | -8.03 ± 4.655 | 1.54 ± 2.122 |
| Week 14 | -1.75 ± 3.808 | -8.60 ± 3.161 | -9.64 ± 6.112 | 2.73 ± 2.679 |
| percentage of participants | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| At Least a ≥5% Reduction in Body Weight | 16.7 (0.9 to 58.2) | 85.7 (56.7 to 100.0) | 75.0 (40.0 to 95.4) | 0 (0.0 to 34.8) |
| At Least a ≥10% Reduction in Body Weight | 0 (NA to NA) | 14.3 (0.0 to 44.3) | 37.5 (11.1 to 71.1) | 0 (0.00 to 34.8) |
BMI was calculated as weight (kg)/height (m\^2).
| percentage of participants | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| At Least a ≥5% Reduction in BMI | 16.7 (0.9 to 58.2) | 85.7 (56.7 to 100.0) | 75.0 (40.0 to 95.4) | 0 (0.0 to 34.8) |
| At Least a ≥10% Reduction in BMI | 0 (NA to NA) | 14.3 (0.0 to 44.3) | 37.5 (11.1 to 71.1) | 0 (0.00 to 34.8) |
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest.
| centimeters | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Week 6 | -1.42 ± 1.469 | -4.90 ± 1.298 | -7.20 ± 5.738 | -3.97 ± 4.875 |
| Week 10 | -5.02 ± 5.226 | -4.50 ± 2.956 | -5.60 ± 4.840 | -1.94 ± 3.208 |
| Week 14 | -2.73 ± 3.822 | -7.75 ± 1.787 | -6.17 ± 6.275 | 1.49 ± 2.060 |
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
| percentage change | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Week 6 | -1.22 ± 1.236 | -4.73 ± 1.534 | -6.00 ± 4.708 | -4.18 ± 5.206 |
| Week 10 | -4.20 ± 4.307 | -4.40 ± 2.844 | -4.79 ± 3.841 | -1.94 ± 3.453 |
| Week 14 | -2.17 ± 2.904 | -7.39 ± 1.842 | -5.17 ± 5.291 | 1.19 ± 1.937 |
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference.
| ratio | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Week 6 | -0.01 ± 0.031 | 0.00 ± 0.028 | -0.03 ± 0.035 | -0.05 ± 0.053 |
| Week 10 | -0.02 ± 0.027 | 0.02 ± 0.049 | 0.01 ± 0.056 | -0.04 ± 0.041 |
| Week 14 | -0.02 ± 0.035 | -0.01 ± 0.031 | -0.02 ± 0.028 | 0.02 ± 0.029 |
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
| percentage change | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Week 6 | -0.53 ± 3.075 | 0.33 ± 3.158 | -3.41 ± 3.449 | -4.90 ± 5.371 |
| Week 10 | -1.71 ± 2.723 | 2.51 ± 5.599 | 1.24 ± 5.688 | -3.77 ± 4.004 |
| Week 14 | -1.79 ± 3.506 | -1.41 ± 3.416 | -2.31 ± 2.791 | 2.12 ± 3.078 |
Body composition included fat and lean body mass and was assessed by dual energy x-ray absorptiometry (DEXA).
| kilograms | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Body Fat Mass | 3.07 ± 12.531 | -5.30 ± 3.026 | -5.65 ± 4.990 | 1.11 ± 2.466 |
| Body Lean Mass | -3.09 ± 3.092 | -2.58 ± 2.192 | -3.35 ± 3.151 | 0.95 ± 1.450 |
Body composition included fat and lean body mass and was assessed by DEXA. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
| percentage change | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Body Fat Mass | 12.92 ± 40.349 | -11.43 ± 3.639 | -11.79 ± 8.134 | 2.72 ± 5.919 |
| Body Lean Mass | -4.76 ± 5.699 | -4.51 ± 2.864 | -6.20 ± 5.890 | 1.68 ± 2.714 |
Participants who were able to validly and reliably self-report were administered "Hunger Questions for Participants ≥12 Years of Age©." This questionnaire comprised 2 items (average and most hunger) that were designed to be evaluated separately (rather than as a composite score). Each item asked participants to rate their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all and 10 = hungriest possible) with a recall period of 24 hours. Data reported are for mean change from baseline in the weekly average daily most hunger score.
| score on a scale | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Treatment Phase: Mean Change From Baseline in the Weekly Average of the Daily Most Hunger Score | -2.07 ± 1.169 | -2.77 ± 1.486 | -2.84 ± 2.299 | -0.77 ± 1.674 |
Participants who were able to self-report were administered the Symptoms of Hyperphagia: Patient© Version. The questionnaire consisted of 4 items related to the frequency of a participant's hyperphagia symptoms on a scale (never \[score 0\], 1 or 2 times \[score 1\], 3 or more times \[score 2\]) over the previous 24 hours. Caregivers of participants who could not self report were administered the Symptoms of Hyperphagia: Caregiver© Version which consisted of 5 items that included caregivers assessing the frequency of hyperphagia symptoms on a scale (never \[score 0\], 1 or 2 times \[score 1\], 3 or more times \[score 2\]) over the previous 24 hours for the person in their care. The composite score was derived by adding up all item scores and dividing by total number of items answered. The full range of the composite score was 0-2, with higher scores representing more hyperphagia. Data are reported for mean change from baseline in weekly average of symptoms of hyperphagia composite score.
| score on a scale | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Treatment Phase: Mean Change From Baseline in the Weekly Average of the Symptoms of Hyperphagia Composite Score | -0.49 ± 0.409 | -0.25 ± 0.273 | -0.21 ± 0.239 | -0.23 ± 0.255 |
BMI was calculated as weight (kg)/height (m\^2).
| kg/m^2 | Open-label Extension Phase: Bivamelagon 200 mg to 600 mg | Open-label Extension Phase: Bivamelagon 400 mg to 600 mg | Open-label Extension Phase: Bivamelagon 600 mg to 600 mg | Open-label Extension Phase: Placebo to Bivamelagon 600 mg |
|---|---|---|---|---|
| Week 28 | -3.14 ± 1.958 | -4.14 ± 2.438 | -5.64 ± 3.743 | -1.90 ± 1.745 |
| Week 52 | -2.56 ± 4.373 | -3.90 ± 3.487 | -6.98 ± 5.756 | -3.15 ± 2.159 |
BMI was calculated as weight (kg)/height (m\^2). Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
| percentage change | Open-label Extension Phase: Bivamelagon 200 mg to 600 mg | Open-label Extension Phase: Bivamelagon 400 mg to 600 mg | Open-label Extension Phase: Bivamelagon 600 mg to 600 mg | Open-label Extension Phase: Placebo to Bivamelagon 600 mg |
|---|---|---|---|---|
| Week 28 | -8.51 ± 5.658 | -11.73 ± 7.265 | -13.60 ± 8.893 | -5.53 ± 5.000 |
| Week 52 | -6.66 ± 11.880 | -10.77 ± 10.386 | -16.58 ± 13.174 | -8.66 ± 6.095 |
| kilograms | Open-label Extension Phase: Bivamelagon 200 mg to 600 mg | Open-label Extension Phase: Bivamelagon 400 mg to 600 mg | Open-label Extension Phase: Bivamelagon 600 mg to 600 mg | Open-label Extension Phase: Placebo to Bivamelagon 600 mg |
|---|---|---|---|---|
| Week 28 | -5.27 ± 8.273 | -11.33 ± 7.316 | -13.70 ± 10.469 | -5.04 ± 7.205 |
| Week 52 | -3.50 ± 14.460 | -11.18 ± 9.845 | -17.31 ± 15.747 | -8.66 ± 9.502 |
Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
| percentage change | Open-label Extension Phase: Bivamelagon 200 mg to 600 mg | Open-label Extension Phase: Bivamelagon 400 mg to 600 mg | Open-label Extension Phase: Bivamelagon 600 mg to 600 mg | Open-label Extension Phase: Placebo to Bivamelagon 600 mg |
|---|---|---|---|---|
| Week 28 | -3.61 ± 6.703 | -11.22 ± 7.608 | -13.11 ± 8.835 | -4.72 ± 5.272 |
| Week 52 | -0.77 ± 12.846 | -10.56 ± 10.264 | -16.06 ± 12.899 | -7.08 ± 7.020 |
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest.
| centimeters | Open-label Extension Phase: Bivamelagon 200 mg to 600 mg | Open-label Extension Phase: Bivamelagon 400 mg to 600 mg | Open-label Extension Phase: Bivamelagon 600 mg to 600 mg | Open-label Extension Phase: Placebo to Bivamelagon 600 mg |
|---|---|---|---|---|
| Week 28 | -3.33 ± 5.702 | -8.45 ± 5.218 | -10.30 ± 7.208 | -5.06 ± 4.970 |
| Week 52 | -3.18 ± 9.899 | -6.73 ± 6.230 | -14.47 ± 10.224 | -4.30 ± 12.325 |
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
| percentage change | Open-label Extension Phase: Bivamelagon 200 mg to 600 mg | Open-label Extension Phase: Bivamelagon 400 mg to 600 mg | Open-label Extension Phase: Bivamelagon 600 mg to 600 mg | Open-label Extension Phase: Placebo to Bivamelagon 600 mg |
|---|---|---|---|---|
| Week 28 | -2.57 ± 4.466 | -8.19 ± 5.945 | -8.92 ± 6.441 | -5.09 ± 5.177 |
| Week 52 | -2.40 ± 8.141 | -6.31 ± 5.773 | -12.22 ± 8.797 | -3.30 ± 12.237 |
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference.
| ratio | Open-label Extension Phase: Bivamelagon 200 mg to 600 mg | Open-label Extension Phase: Bivamelagon 400 mg to 600 mg | Open-label Extension Phase: Bivamelagon 600 mg to 600 mg | Open-label Extension Phase: Placebo to Bivamelagon 600 mg |
|---|---|---|---|---|
| Week 28 | -0.01 ± 0.039 | 0.02 ± 0.066 | -0.00 ± 0.074 | -0.02 ± 0.044 |
| Week 52 | -0.03 ± 0.036 | -0.00 ± 0.049 | -0.04 ± 0.036 | -0.03 ± 0.051 |
The waist circumference was defined as the minimal abdominal circumference located midway between the lower rib margin and the iliac crest. The hip circumference was defined as the widest circumference around the buttocks. The waist-to-hip ratio was calculated as waist circumference divided by hip circumference. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
| percentage change | Open-label Extension Phase: Bivamelagon 200 mg to 600 mg | Open-label Extension Phase: Bivamelagon 400 mg to 600 mg | Open-label Extension Phase: Bivamelagon 600 mg to 600 mg | Open-label Extension Phase: Placebo to Bivamelagon 600 mg |
|---|---|---|---|---|
| Week 28 | -1.37 ± 3.936 | 2.15 ± 7.636 | 0.19 ± 8.635 | -2.42 ± 4.774 |
| Week 52 | -3.39 ± 3.622 | -0.44 ± 5.403 | -4.07 ± 3.362 | -3.05 ± 5.289 |
Body composition included fat and lean body mass and was assessed by DEXA.
| kilograms | Open-label Extension Phase: Bivamelagon 200 mg to 600 mg | Open-label Extension Phase: Bivamelagon 400 mg to 600 mg | Open-label Extension Phase: Bivamelagon 600 mg to 600 mg | Open-label Extension Phase: Placebo to Bivamelagon 600 mg |
|---|---|---|---|---|
| Body Fat Mass | -5.55 ± 7.853 | -9.47 ± 6.030 | -13.26 ± 9.929 | -4.70 ± 4.971 |
| Body Lean Mass | -2.32 ± 5.007 | -5.54 ± 3.242 | -4.87 ± 7.032 | -2.39 ± 5.731 |
Body composition included fat and lean body mass and was assessed by DEXA. Percentage change from baseline was calculated as: (post-baseline result - baseline result) / baseline result\*100%.
| percentage change | Open-label Extension Phase: Bivamelagon 200 mg to 600 mg | Open-label Extension Phase: Bivamelagon 400 mg to 600 mg | Open-label Extension Phase: Bivamelagon 600 mg to 600 mg | Open-label Extension Phase: Placebo to Bivamelagon 600 mg |
|---|---|---|---|---|
| Body Fat Mass | -9.14 ± 14.707 | -20.12 ± 8.170 | -28.74 ± 17.588 | -10.40 ± 9.936 |
| Body Lean Mass | -1.87 ± 6.464 | -10.83 ± 7.516 | -8.40 ± 12.617 | -3.55 ± 8.115 |
A TEAE was any undesirable and unintended medical event occurring to a participant in a clinical study and which did not necessarily have a causal relationship with the study drug, with onset or worsening after the start of study drug. AESIs were events of scientific and medical interest specific to further the understanding of the safety profile of the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Any TEAE | 6 | 7 | 8 | 6 |
| Any AESI | 2 | 3 | 0 | 1 |
A TEAE was any undesirable and unintended medical event occurring to a participant in a clinical study and which does not necessarily have a causal relationship with the study drug, with onset or worsening after the start of study drug. AESIs were events of scientific and medical interest specific to the further understanding of the safety profile of the study drug. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Open-label Extension Phase: Bivamelagon 200 mg to 600 mg | Open-label Extension Phase: Bivamelagon 400 mg to 600 mg | Open-label Extension Phase: Bivamelagon 600 mg to 600 mg | Open-label Extension Phase: Placebo to Bivamelagon 600 mg |
|---|---|---|---|---|
| Any TEAE | 6 | 5 | 7 | 7 |
| Any AESI | 3 | 1 | 0 | 4 |
TEAEs were evaluated by the investigator according to the definitions below using the following guidelines: * Mild - Asymptomatic or mild symptoms; clinical or diagnostic observations only; no intervention indicated; no disruption to daily activity. * Moderate - Discomfort sufficient to reduce or affect normal daily activity. * Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; inability to work or perform normal daily activity. * Life-threatening consequences; urgent intervention indicated. * Fatal outcome. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo |
|---|---|---|---|---|
| Any Mild TEAE | 5 | 2 | 4 | 4 |
| Any Moderate TEAE | 1 | 3 | 4 | 0 |
| Any Severe TEAE | 0 | 2 | 0 | 2 |
| Any Life-threatening TEAE | 0 | 0 | 0 | 0 |
| Any Fatal TEAE | 0 | 0 | 0 | 0 |
TEAEs were evaluated by the investigator according to the definitions below using the following guidelines: * Mild - Asymptomatic or mild symptoms; clinical or diagnostic observations only; no intervention indicated; no disruption to daily activity. * Moderate - Discomfort sufficient to reduce or affect normal daily activity. * Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; inability to work or perform normal daily activity. * Life-threatening consequences; urgent intervention indicated. * Fatal outcome. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Open-label Extension Phase: Bivamelagon 200 mg to 600 mg | Open-label Extension Phase: Bivamelagon 400 mg to 600 mg | Open-label Extension Phase: Bivamelagon 600 mg to 600 mg | Open-label Extension Phase: Placebo to Bivamelagon 600 mg |
|---|---|---|---|---|
| Any Mild TEAE | 0 | 3 | 2 | 3 |
| Any Moderate TEAE | 4 | 1 | 3 | 4 |
| Any Severe TEAE | 2 | 0 | 2 | 0 |
| Any Life-threatening TEAE | 0 | 1 | 0 | 0 |
| Any Fatal TEAE | 0 | 0 | 0 | 0 |
Pharmacokinetic (PK) parameters were derived using noncompartmental methods. Cmax was obtained directly from the observed concentration versus time data. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.
| nanograms per milliliter (ng/mL) | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg |
|---|---|---|---|
| Week 0 | 4609.8 ± 75.2 | 3624.9 ± 78.9 | 3895.2 ± 86.4 |
| Week 10 | 5764 ± 61.4 | 10047.9 ± 48.2 | NA ± NA |
PK parameters were derived using noncompartmental methods. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.
| hours | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg |
|---|---|---|---|
| Week 0 | 3.11 (1.00 to 4.03) | 1.88 (0.83 to 2.02) | 1.98 (1.00 to 4.00) |
| Week 10 | 1.17 (1.00 to 2.00) | 2.43 (0.85 to 4.00) | NA (NA to NA) |
PK parameters were derived using noncompartmental methods.AUC0-t was calculated by the linear up/log down trapezoidal summation. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.
| nanogram-hours per milliliter (h*ng/mL) | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg |
|---|---|---|---|
| Week 0 | 29540 ± 69.2 | 27870 ± 96.1 | 31780 ± 59.6 |
| Week 10 | 38250 ± 58.8 | 102400 ± 91.6 | NA ± NA |
PK parameters were derived using noncompartmental methods. At Week 0, all participants received bivamelagon 200 mg QD. At Week 10, participants received their maximum assigned bivamelagon dose QD.
| ng/mL | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg |
|---|---|---|---|
| Week 1 | 297.8 ± 44.6 | 545.5 ± 118.9 | NA ± NA |
| Week 2 | 339.6 ± 42.0 | 1024.6 ± 172.2 | NA ± NA |
| Week 6 | 365.7 ± 39.6 | 1136.5 ± 126.1 | NA ± NA |
| Week 10 | 441.8 ± 51.5 | 2166.7 ± 212.7 | NA ± NA |
| Week 14 | 343.1 ± 60.7 | 1001 ± 210.1 | NA ± NA |
Collected over Treatment Phase: Day 1 to Week 14. Open-label Extension Phase: Week 14 to Week 56. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Phase: Bivamelagon 200 mg | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Treatment Phase: Bivamelagon 400 mg | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Treatment Phase: Bivamelagon 600 mg | 0/8 (0%) | 0/8 (0%) | 8/8 (100%) |
| Treatment Phase: Placebo | 0/7 (0%) | 1/7 (14.3%) | 6/7 (85.7%) |
| Open-label Extension Phase: Bivamelagon 200 mg to 600 mg | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Open-label Extension Phase: Bivamelagon 400 mg to 600 mg | 0/6 (0%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Open-label Extension Phase: Bivamelagon 600 mg to 600 mg | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Open-label Extension Phase: Placebo to Bivamelagon 600 mg | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Event | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo | Open-label Extension Phase: Bivamelagon 200 mg to 600 mg | Open-label Extension Phase: Bivamelagon 400 mg to 600 mg | Open-label Extension Phase: Bivamelagon 600 mg to 600 mg | Open-label Extension Phase: Placebo to Bivamelagon 600 mg |
|---|---|---|---|---|---|---|---|---|
| Anaphylactic reactionImmune system disorders | 0/6 | 0/7 | 0/8 | 0/7 | 0/6 | 1/6 | 0/7 | 0/7 |
| HyponatraemiaMetabolism and nutrition disorders | 0/6 | 0/7 | 0/8 | 0/7 | 1/6 | 0/6 | 0/7 | 0/7 |
| Tonsillar hypertrophyRespiratory, thoracic and mediastinal disorders | 0/6 | 0/7 | 0/8 | 0/7 | 1/6 | 0/6 | 0/7 | 0/7 |
| HaematocheziaGastrointestinal disorders | 0/6 | 1/7 | 0/8 | 0/7 | 0/6 | 0/6 | 0/7 | 0/7 |
| Chest painGeneral disorders | 0/6 | 0/7 | 0/8 | 1/7 | 0/6 | 0/6 | 0/7 | 0/7 |
| GastroenteritisInfections and infestations | 0/6 | 0/7 | 0/8 | 0/7 | 0/6 | 0/6 | 1/7 | 0/7 |
| Event | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo | Open-label Extension Phase: Bivamelagon 200 mg to 600 mg | Open-label Extension Phase: Bivamelagon 400 mg to 600 mg | Open-label Extension Phase: Bivamelagon 600 mg to 600 mg | Open-label Extension Phase: Placebo to Bivamelagon 600 mg |
|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 6/6 | 5/7 | 4/8 | 2/7 | 4/6 | 3/6 | 1/7 | 4/7 |
| DiarrhoeaGastrointestinal disorders | 2/6 | 5/7 | 3/8 | 1/7 | 3/6 | 2/6 | 1/7 | 3/7 |
| VomitingGastrointestinal disorders | 2/6 | 4/7 | 4/8 | 2/7 | 4/6 | 4/6 | 1/7 | 5/7 |
| HeadacheNervous system disorders | 1/6 | 5/7 | 1/8 | 2/7 | 1/6 | 2/6 | 1/7 | 3/7 |
| Abdominal painGastrointestinal disorders | 1/6 | 2/7 | 1/8 | 0/7 | 0/6 | 1/6 | 1/7 | 3/7 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/6 | 0/7 | 0/8 | 0/7 | 0/6 | 0/6 | 0/7 | 0/7 |
| Viral upper respiratory tract infectionInfections and infestations | 2/6 | 0/7 | 0/8 | 1/7 | 0/6 | 0/6 | 0/7 | 0/7 |
| NasopharyngitisInfections and infestations | 1/6 | 2/7 | 0/8 | 1/7 | 1/6 | 2/6 | 1/7 | 0/7 |
| FatigueGeneral disorders | 1/6 | 2/7 | 1/8 | 0/7 | 0/6 | 2/6 | 0/7 | 1/7 |
| Skin hyperpigmentationSkin and subcutaneous tissue disorders | 0/6 | 1/7 | 0/8 | 1/7 | 2/6 | 0/6 | 0/7 | 2/7 |
The Modified Intent-to-Treat (mITT) set included all randomized participants in the Treatment Phase who were exposed to at least one dose of study drug.
| Age, Continuous(years) | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo | Total |
|---|---|---|---|---|---|
| Mean | 20.2 ± 9.15 | 21.0 ± 7.94 | 31.9 ± 23.02 | 27.0 ± 20.17 | 25.4 ± 16.78 |
| Sex: Female, Male(Participants) | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo | Total |
|---|---|---|---|---|---|
| Female | 3 | 4 | 3 | 3 | 13 |
| Male | 3 | 3 | 5 | 4 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 2 | 4 |
| Not Hispanic or Latino | 6 | 7 | 6 | 5 | 24 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Treatment Phase: Bivamelagon 200 mg | Treatment Phase: Bivamelagon 400 mg | Treatment Phase: Bivamelagon 600 mg | Treatment Phase: Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 2 | 1 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 | 2 |
| White | 5 | 5 | 5 | 6 | 21 |
| More than one race | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2024 to primary completion in Feb 2026, 18 months.
Results were first posted in Oct 2026, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bivamelagon
Rhythm Pharmaceuticals, Inc. →